Major trial launches for deadly pancreatic cancer
NCT ID NCT07238283
Summary
This large, late-stage trial is comparing a new three-drug combination to the current standard treatment for advanced pancreatic cancer that has spread. It aims to see if the new approach helps patients live longer or better control their cancer. The study will enroll 662 adults with newly diagnosed metastatic pancreatic cancer who haven't had prior treatment for their spread disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIRST-LINE TREATMENT OF METASTATIC PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.